CARLSBAD, Calif., Aug. 29, 2018 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense
therapeutics, today announced that management will present a
company overview at the following investor conferences:
- 2018 Wells Fargo Healthcare Conference on Wednesday, September 5, 2018 in Boston, MA; and
- Morgan Stanley 16th Annual Global Healthcare
Conference on Wednesday, September 12,
2018 in New York, NY.
The above listed dates are subject to change. Details on
presentation times or changes to presentation dates can be found on
the Company's website. Please check www.ionispharma.com for the
latest information.
A live webcast of the presentations will be available on the
"Investors & Media" section of the Ionis website. The replays
will be available within 48 hours and will be archived for a
limited time.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases. Using
its proprietary antisense technology, Ionis has created a large
pipeline of first-in-class or best-in-class drugs, with over 40
drugs in development. SPINRAZA® (nusinersen) has been
approved in global markets for the treatment of spinal muscular
atrophy (SMA). Biogen is responsible for commercializing SPINRAZA.
TEGSEDITM (inotersen) and WAYLIVRATM
(volanesorsen) are two antisense drugs that Ionis discovered and
successfully advanced through Phase 3 studies. TEGSEDI is approved
in the E.U. for the treatment of stage 1 or stage 2 polyneuropathy
in adult patients with hereditary transthyretin amyloidosis, or
hATTR, and is currently under regulatory review in the U.S. and
Canada. WAYLIVRA is also under
regulatory review for marketing approval in the E.U. and
Canada for the treatment of
patients with familial chylomicronemia syndrome, or FCS. WAYLIVRA
is also in a Phase 3 study in patients with familial partial
lipodystrophy, or FPL. Akcea Therapeutics, an affiliate of Ionis
focused on developing and commercializing drugs to treat patients
with serious and rare diseases, will commercialize TEGSEDI and
WAYLIVRA, if approved. Ionis' patents provide strong and extensive
protection for its drugs and technology. Additional information
about Ionis is available at www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding the therapeutic and
commercial potential of Ionis' technologies and products in
development, including SPINRAZA, TEGSEDITM (inotersen)
and WAYLIVRATM (volanesorsen). Any statement describing
Ionis' goals, expectations, financial or other projections,
intentions or beliefs is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the
process of discovering, developing and commercializing drugs that
are safe and effective for use as human therapeutics, and in the
endeavor of building a business around such drugs. Ionis'
forward-looking statements also involve assumptions that, if they
never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such
forward-looking statements. Although Ionis' forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Ionis. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Ionis'
programs are described in additional detail in Ionis' annual report
on Form 10-K for the year ended December 31,
2017, and most recent Form 10-Q quarterly filing, which are
on file with the SEC. Copies of this and other documents are
available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals,
Inc. SPINRAZA® is a registered trademark of Biogen.
View original content with
multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-present-at-upcoming-investor-conferences-300703774.html
SOURCE Ionis Pharmaceuticals, Inc.